Currently, seven CAR T-cell therapies 1 and six T-cell engager therapies have been approved by the FDA. 2 Despite these advancements and their clear benefits, immunotherapy-based treatments carry ...
Medpage Today on MSN
CAR-T Drug for Myeloma Hit With New Boxed Warning
Ciltacabtagene autoleucel (cilta-cel; Carvykti) for multiple myeloma has a new boxed warning for immune effector ...
At LSX in Boston last month, editor-in-chief Jonah Comstock spoke with Teresa Whalen, the CEO of CytoAgents, a clinical-stage ...
HealthDay News — Antithymocyte globulin (ATG) 2.5 and 0.5mg/kg reduces loss of β-cell function in young people with recent-onset type 1 diabetes, according to a study published online September 18 in ...
Collaboration between community practices and academic institutions is crucial for administering bispecific antibodies, with ...
Japanese scientists successfully eliminated cancer tumors using live bacteria, a new therapy that acts independently of the ...
Credit: Celltrion CRS is a life-threatening condition that results in the excessive release of cytokines into the bloodstream, causing inflammation and damage to organs and tissues. With the newly ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...
A look back at last week’s most-viewed content highlights how AI-driven monitoring could improve management of cytokine ...
Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer Children and young adults with CD19-positive relapsed ...
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback